The use and number of cognitive-enhancing drugs is likely to grow substantially in the coming years, and researchers must prioritize the potential advantages and dangers of their use in healthy subjects, according to U.K. neuroscientists writing in The Lancet Psychiatry journal.
The use and number of cognitive-enhancing drugs is likely to grow substantially in the coming years, and researchers must prioritize the potential advantages and dangers of their use in healthy subjects, according to U.K. neuroscientists writing in The Lancet Psychiatry journal.
“Reliable evidence is crucial for a balanced view on the risks and benefits of these drugs and to set out clear regulatory guidelines for their use,” wrote Prof. Barbara Sahakian and Dr. Sharon Morein-Zamir from the University of Cambridge, adding that the government, pharmaceutical industry, and national medical organizations need to work together to look at the harms and benefits of long-term use of cognitive-enhancing drugs.
Drugs such as methylphenidate (Ritalin) and modafinil (Provigil) are being used by healthy individuals to improve concentration, memory, and other aspects of cognitive performance, but very little is known about the long-term effects of this non-medical use, noted the authors. People are using the drugs to gain a competitive edge at school, university, or work, and for maintaining attention and performance when sleep-deprived or jet-lagged, and student use in the U.S. varies between 5% and 35%, they wrote. This might only be the tip of the iceberg and is unlikely to be representative of usage in professional or older populations, they added.
Most cognitive enhancers have been developed by the pharmaceutical industry to treat the effects of impaired cognition in conditions such as Alzheimer’s disease, attention deficit hyperactivity disorders, and schizophrenia. But non-medical use raises safety and ethical concerns including side effects and potential abuse, particularly from sourcing on the internet, according to Sahakian and Morein-Zamer.
“Present cognitive-enhancing drugs have wide ranging effects and side effects and are not predictable. We also know next to nothing about their long-terms effects in healthy people,” they pointed out.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.